Zurcher Kantonalbank (Zurich Cantonalbank) Provention Bio, Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$32.8 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 08, 2023	BUY	$6.7 - $24.21 $16,066 - $58,055	2,398 Added 17.86%	15,825 $381,000
Q4 2022 Feb 01, 2023	BUY	$4.52 - $10.57 $38,144 - $89,200	8,439 Added 169.19%	13,427 $141,000
Q1 2022 Apr 21, 2022	SELL	$3.4 - $7.88 $10,087 - $23,379	-2,967 Reduced 37.3%	4,988 $37,000
Q4 2021 Feb 01, 2022	SELL	$5.59 - $7.39 $1,721 - $2,276	-308 Reduced 3.73%	7,955 $45,000
Q3 2021 Nov 15, 2021	BUY	$5.66 - $8.33 $90 - $133	16 Added 0.19%	8,263 $53,000
Q2 2021 Jul 30, 2021	BUY	$6.71 - $11.04 $2,288 - $3,764	341 Added 4.31%	8,247 $70,000
Q1 2021 May 03, 2021	BUY	$10.12 - $19.45 $29,530 - $56,755	2,918 Added 58.5%	7,906 $83,000
Q3 2020 Nov 06, 2020	BUY	$10.34 - $15.2 $31,547 - $46,375	3,051 Added 157.51%	4,988 $64,000
Q2 2020 Jul 28, 2020	BUY	$7.81 - $17.0 $15,127 - $32,929	1,937 New	1,937 $27,000

Others Institutions Holding PRVB

# of Institutions

Shares Held

170K

Call Options Held

Put Options Held

Odey Asset Management Group LTD London, X0

170K
Shares

$0
1.36% of portfolio

View Full List

About Provention Bio, Inc.

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

More about PRVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account